What is adenoid cystic carcinoma of the breast?
Adenoid cystic carcinoma of the breast (ACCB) is a very rare type of breast cancer, making up well under 1% of breast cancers. It is better known as a cancer of the salivary glands, but the same type of tumour can also develop in the breast. Under the microscope, its cells form a pattern of small round spaces that looks like Swiss cheese, described as cribriform.
ACCB is unusual because of its receptor status. Most cases are triple-negative: they do not have oestrogen or progesterone receptors and do not overproduce HER2. In ordinary breast cancers, triple-negative disease tends to be aggressive. Classic ACCB is the opposite: it usually grows slowly, rarely spreads to lymph nodes and has an excellent outlook (Neilson et al., 2025).
Many adenoid cystic carcinomas carry a typical gene change, the MYB::NFIB fusion, or other alterations that switch on the MYB gene. This feature is shared with salivary gland adenoid cystic carcinoma and helps confirm the diagnosis.
Because ACCB behaves gently, experts increasingly favour less aggressive treatment. Surgery is the mainstay, and radiotherapy is often recommended after breast-conserving surgery. Chemotherapy rarely seems to help (Li et al., 2022). A small number of tumours, especially the solid-basaloid form, behave more aggressively and may need fuller treatment.
1. Key facts at a glance
| Feature | Details |
|---|---|
| Type of cancer | Rare special type of invasive breast carcinoma |
| How common | Well under 1% of breast cancers |
| Typical age | Usually 50s-60s; median 61 in one large analysis |
| Receptor status | Usually triple-negative (ER, PR and HER2 negative) |
| Genetic hallmark | MYB::NFIB fusion or other MYB activation |
| Lymph node spread | Uncommon |
| Main treatment | Surgery, often with radiotherapy |
| Chemotherapy | Rarely beneficial for classic tumours |
| Outlook | Generally excellent |
2. Types
| Type | Description | Behaviour |
|---|---|---|
| Classic ACCB | Cribriform, tubular and trabecular patterns with two cell types | Favourable |
| Solid-basaloid ACCB | Sheets of basaloid cells with fewer gland-like spaces | More aggressive; higher risk of spread |
| ACCB with high-grade transformation | Areas of high-grade carcinoma within the tumour | Aggressive |
How ACCB differs from typical triple-negative breast cancer
| Feature | Classic ACCB | Typical triple-negative breast cancer |
|---|---|---|
| Growth rate | Slow | Often fast |
| Lymph node spread | Rare | More common |
| Distant spread | Uncommon; can occur late, often to lungs | More common, often early |
| Benefit from chemotherapy | Not shown | Substantial |
| Outlook | Excellent | More guarded |
Adenoid cystic carcinoma of the breast and salivary glands
| Feature | Breast | Salivary gland |
|---|---|---|
| Gene change | MYB::NFIB common | MYB::NFIB common |
| Spread along nerves | Uncommon | Common |
| Lymph node spread | Rare | Variable |
| Outlook | Usually better | Often slow but persistent disease |
3. Causes and risk factors
The cause of ACCB is not known.
| Factor | Notes |
|---|---|
| Female sex | Almost all patients are women; male cases are very rare |
| Age | Mostly affects women after 50 |
| Gene fusion in tumour cells | Acquired; not inherited |
| Family history and BRCA | No clear link established |
| General breast cancer risk factors | Their role in ACCB is uncertain |
4. How does it look
On imaging
A multi-centre imaging study showed that ACCB can look benign on scans (Guldogan et al., 2023).
| Test | Typical findings |
|---|---|
| Mammogram | Round or oval mass, sometimes with well-defined margins |
| Ultrasound | Oval mass parallel to the skin; may look grey-white or even cyst-like |
| MRI | Bright on T2 images, restricted diffusion, often even enhancement |
| Doppler ultrasound | Often no blood flow seen |
In that study, combining the features from all imaging tests correctly placed every lesion in a suspicious category. However, most were only mildly suspicious (BI-RADS 4A), showing how easily these tumours can be underestimated.
Under the microscope
| Feature | Description |
|---|---|
| Pattern | Cribriform, tubular, trabecular or solid |
| Two cell types | Duct-lining (epithelial) cells and outer basal/myoepithelial cells |
| Spaces | True glandular spaces and pseudo-spaces filled with basement membrane material |
| Stains | CD117 (KIT) often positive; MYB positive |
| Grade | Classic forms are usually low grade |
Why the diagnosis can be difficult
ACCB is rare, so many pathologists see only a few cases in their career. On a small needle biopsy, it can be confused with benign conditions such as collagenous spherulosis, or with other cancers such as invasive cribriform carcinoma, which is hormone receptor-positive and treated differently. For this reason, the biopsy or the removed tumour is often sent for a second opinion from a specialist breast pathologist.
Special stains help. The presence of two cell types, staining for CD117 and MYB, and in some cases a test for the MYB::NFIB fusion, all support the diagnosis. Getting the diagnosis right matters, because it can spare people from treatments they do not need.
5. Symptoms
Common symptoms
- A firm, painless or tender lump in the breast
- A lump often lying under or near the nipple area
- No symptoms, with the lesion found on a mammogram
Less common symptoms
| Symptom | Notes |
|---|---|
| Breast pain or tenderness | More common than in other breast cancers |
| Skin changes | Rare |
| Nipple discharge | Rare |
| Lump in the armpit | Uncommon, as nodal spread is rare |
| Cough or breathlessness | Rare; may indicate lung spread |
When to seek medical advice
See a doctor if you notice a new breast lump or other breast change. Attend routine screening when invited.
6. Diagnosis
| Test | Purpose |
|---|---|
| Clinical breast examination | Assesses the lump and the armpit |
| Mammogram and ultrasound | Main imaging tests |
| Core needle biopsy | Confirms cancer and type |
| Receptor and HER2 tests | Usually negative |
| MYB staining or gene testing | Supports the diagnosis |
| Specialist pathology review | Separates ACCB from look-alikes such as cribriform carcinoma or collagenous spherulosis |
| MRI | Selected cases, for example to assess extent |
| CT scans | For larger, solid-basaloid or high-grade tumours |
Staging uses the standard breast cancer TNM system. In a large SEER-based study, almost all patients (99.5%) were diagnosed at stage I or II (Li et al., 2022).
7. Treatment
There are no randomised trials in ACCB. Treatment advice comes from population databases, case series and expert reviews (Neilson et al., 2025).
Surgery
| Option | Notes |
|---|---|
| Breast-conserving surgery | Suitable for most tumours |
| Mastectomy | For larger tumours or patient preference |
| Clear margins | Important, as local recurrence can occur |
| Sentinel lymph node biopsy | Commonly done, although nodal spread is rare; omission is increasingly discussed |
Radiotherapy
| Situation | Approach |
|---|---|
| After breast-conserving surgery | Usually recommended |
| After mastectomy | Considered for large tumours, close margins or node involvement |
An analysis of 488 SEER patients found better overall survival in those who had radiotherapy after surgery (Gomez-Seoane et al., 2021). The authors recommended considering radiotherapy, especially for patients with risk factors such as nodal spread or high grade.
Chemotherapy
A study of 661 patients from American and Chinese databases found that chemotherapy after surgery did not improve overall or breast cancer-specific survival, even in higher-risk subgroups (Li et al., 2022). Only about one in eight patients had received it.
| Situation | Chemotherapy role |
|---|---|
| Classic, early-stage ACCB | Usually not recommended |
| Solid-basaloid or high-grade ACCB | May be discussed |
| Spread to distant organs | Considered case by case |
Hormone and targeted therapy
| Treatment | Notes |
|---|---|
| Hormone therapy | Rarely useful, as most tumours lack hormone receptors |
| Targeted drugs | Under study, for example agents acting on MYB-related pathways |
| Clinical trials | Recommended for advanced disease |
Summary of current approach
Recent reviews support radiotherapy after surgery, with the option of omitting axillary staging and systemic therapy for many patients (Neilson et al., 2025). Each plan is individual and should be discussed by a breast multidisciplinary team.
Understanding your pathology report
| Term | Meaning |
|---|---|
| ER and PR negative | The tumour does not respond to hormones |
| HER2 negative | HER2-targeted drugs will not help |
| Triple-negative | All three of the above are negative |
| Grade | How abnormal the cells look; classic ACCB is usually low grade |
| Margins | Whether healthy tissue surrounds the removed tumour |
| Solid component | The proportion of solid-basaloid tumour, which affects risk |
Recovery and treatment timeline
| Stage | What to expect |
|---|---|
| Surgery | Usually a day case or one night in hospital |
| First 2 weeks | Wound healing and gentle arm exercises |
| 2-3 weeks after surgery | Full pathology results and treatment plan |
| 4-8 weeks after surgery | Radiotherapy begins, if recommended |
| Radiotherapy course | Usually 1-3 weeks of weekday sessions |
Many people are back to most normal activities within a few weeks of finishing treatment, although tiredness can last longer.
Side effects
| Treatment | Possible side effects |
|---|---|
| Surgery | Pain, bruising, change in breast shape, fluid collection |
| Sentinel node biopsy | Small risk of arm swelling and numbness |
| Radiotherapy | Skin redness, tiredness, breast firmness or swelling |
| Chemotherapy, if used | Tiredness, infection risk, hair loss, nausea |
8. Outlook (prognosis)
| Factor | Effect |
|---|---|
| Classic type | Excellent outlook |
| Solid-basaloid type | Higher risk of recurrence and spread |
| Lymph node involvement | Linked with poorer survival |
| Higher grade or stage | Linked with poorer breast cancer-specific survival |
| No radiotherapy | Linked with poorer survival in database studies |
In the Li et al. (2022) analysis, lymph node spread, higher stage, grade 2 or above and not receiving radiotherapy were linked with worse breast cancer-specific survival.
Distant spread, when it happens, may appear many years after diagnosis, often in the lungs. Long-term follow-up is therefore advisable.
9. Follow-up
| Follow-up | Typical schedule |
|---|---|
| Clinic review | Every 6-12 months for at least 5 years |
| Mammogram | Yearly |
| Chest imaging | If symptoms develop or for higher-risk types |
| Long-term awareness | Report new lumps, cough or breathlessness, even years later |
10. Living with adenoid cystic carcinoma of the breast
- Ask whether your tumour is classic or solid-basaloid, as this affects treatment
- Do not assume triple-negative means aggressive in your case; discuss it with your team
- Keep active and maintain a healthy weight
- Check your breasts and report changes
- Look after your skin during radiotherapy with gentle, unperfumed products
- Wear a soft, supportive bra while the wound heals and during radiotherapy
- Seek support from breast cancer and rare cancer charities
Living well after treatment
Most people with classic ACCB can expect to return to their usual lives. Regular exercise, a balanced diet and limiting alcohol support general health and recovery. Some people feel anxious because their diagnosis is so rare and information is limited; specialist breast care nurses and support groups can help with these concerns.
11. Frequently asked questions
| Question | Answer |
|---|---|
| Is it the same as triple-negative breast cancer? | It is triple-negative, but usually much less aggressive |
| Will I need chemotherapy? | Usually not for classic, early-stage tumours |
| Will I need radiotherapy? | It is often recommended after breast-conserving surgery |
| Do my lymph nodes need checking? | Often a sentinel node biopsy is done, but this may be omitted in some cases |
| Can it come back? | Yes, though uncommonly; late lung spread is possible |
| Is it inherited? | No clear inherited link is known |
| Will I need hormone tablets? | Usually not, because the tumour lacks hormone receptors |
| Can men get it? | Very rarely |
| Why was I told my cancer is triple-negative but low risk? | ACCB is an exception to the usual rule; its biology is different from typical triple-negative cancer |
| Should I have genetic testing? | Ask your team; it depends on your personal and family history rather than the tumour type |
12. Questions to ask your care team
- Is my tumour classic or solid-basaloid?
- What grade and stage is it?
- Do I need sentinel lymph node biopsy?
- Do you recommend radiotherapy, and why?
- Is there any benefit from chemotherapy in my case?
- What follow-up will I need, and for how long?
- Has my biopsy been reviewed by a specialist breast pathologist?
- Who can I contact if I notice new symptoms?
Resources
- Gomez-Seoane, A., Davis, A. and Oyasiji, T. (2021) ‘Treatment of adenoid cystic carcinoma of the breast: is postoperative radiation getting its due credit?’, The Breast, 59, pp. 358-366.
- Guldogan, N. et al. (2023) ‘Adenoid cystic carcinoma of the breast: multimodality imaging findings and review of the literature’, Academic Radiology, 30(6), pp. 1107-1117.
- Li, L., Zhang, D. and Ma, F. (2022) ‘Adenoid cystic carcinoma of the breast may be exempt from adjuvant chemotherapy’, Journal of Clinical Medicine, 11(15), 4477.
- Neilson, T. et al. (2025) ‘Adenoid cystic carcinoma of the breast: a narrative review and update on management’, Cancers, 17(7), 1079.
- National Cancer Institute (2026) Breast Cancer Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/breast/hp/breast-treatment-pdq (Accessed: October 2026).
Prepared by the editorial team, October 2026.